Aprea Therapeutics (APRE) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.0 million vs $7.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | BOLT |
|---|---|---|
| Share price | $0.5582 | $3.65 |
| Market cap | $7.03M | $7.03M |
| 1-day change | -7.74% | +1.39% |
| EPS (TTM) | $-0.95 | $-16.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $7.20 |
| 52-week low | $0.548 | $3.10 |
| Distance from 52-week high | -66.97% | -49.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +568.22% | +694.52% |
| Average volume | 280.14K | 26.26K |
| Shares outstanding | 12.59M | 1.93M |
| Employees | 8 | 23 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Healthcare · Biotechnology · 8 employees
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Healthcare · Biotechnology · 23 employees
APRE vs BOLT FAQ
Which is bigger, Aprea Therapeutics or Bolt Biotherapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.03M compared with $7.03M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and Bolt Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.